ArticleDiscover oncology2026
A comprehensive analysis of palmitoylation related genes in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to identify prognostic genes related to palmitoylation and explore their value in predicting outcomes and treatment response in lung adenocarcinoma (LUAD). We employed the single-sample Gene Set Enrichment Analysis (ssGSEA) algorithm to compute the palmitoylation pathway score(PPS) and utilized lasso regression for feature selection to identify hub palmitoylation pathway score-related genes(PPSGs). A palmitoylation-related prognostic risk score model(PM model) was developed and validated across cohorts. Functional enrichment analysis, immune profiling, and drug sensitivity analyses were performed. Additionally, the expression levels of hub PPSGs were evaluated using qPCR in lung adenocarcinoma cell lines and patient tissue samples. Fifteen hub PPSGs were used to construct the PM model, which demonstrated moderate but consistent predictive accuracy (AUCs: 0.737, 0.693, 0.676 for 1-, 2-, 5-year survival). The risk score derived from the PM model (PM score) correlated with immune suppression and cytoskeleton-related pathways. Clinically, high PM score was associated with advanced stage, male patients, reduced immunotherapy response, and enhanced sensitivity to select chemotherapies. Five key genes (TPPP, FAAH, CACNB1, GLOD5, CCNA2) were validated in local LUAD samples. The PM model serves as a clinically relevant tool for prognosis and treatment prediction in LUAD, highlighting the potential role of palmitoylation in tumor progression and therapy stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.